Novo Nordisk A/S
NVO · Health Technology · Pharmaceuticals: Major · DK
43,158 employees · novonordisk.com
About
Novo Nordisk A/S is a Danish company specializing in the production of insulin and other diabetes medications. Founded in 1923, its headquarters are located in Bagsværd, Denmark. Novo Nordisk is the world's largest manufacturer of insulin and one of the leading companies in the field of diabetes treatment. The history of Novo Nordisk began with the discovery of insulin in 1921. Two Canadian scientists, Frederick Banting and Charles Best, discovered the hidden hormone-producing gland in the pancreas that produces insulin. This discovery ushered in a new era in diabetes treatment. The two scientists sold their discovery to the University of Toronto, and Banting received the Nobel Prize in Medicine in 1923. Following the discovery of insulin, researchers around the world began producing insulin from animal organs. However, insulin derived from animal organs often had lower efficacy and was associated with a higher risk of allergic reactions. Novo Nordisk succeeded in obtaining insulin from human pancreatic cells. In the years following its founding, Novo Nordisk achieved many successes in developing insulin analogs and other diabetes treatments. It was the first company to bring an insulin pump to market and also developed the first oral diabetes medication. Novo Nordisk's business model is specialized in diabetes, but the company also has other business segments. For example, it produced enzymes and proteins for a long time to treat diseases such as cystic fibrosis and hemophilia. However, in 2020, the company decided to focus more on its core business and sold the enzyme and protein division to the French pharmaceutical conglomerate Sanofi. Today, Novo Nordisk is divided into three main areas: diabetes, obesity, and hemophilia. In the diabetes segment, the company produces a wide range of insulin analogs and other diabetes medications. Insulin analogs are specially developed forms of insulin that act faster or slower than natural insulin, thereby allowing for more individualized adjustment and control over diabetes. For the treatment of obesity, Novo Nordisk offers Saxenda, a medication that reduces appetite and boosts metabolism. The company is also working on developing medications to treat other metabolic disorders, such as non-alcoholic fatty liver disease. In the hemophilia segment, Novo Nordisk produces factor VIII concentrates for treating bleeding disorders in hemophilia A patients. Additionally, the company offers laboratory products and services for hemostasis diagnostics, as well as a broad range of clotting factors and antihemophilic factors. The company operates globally, with locations in more than 80 countries. It employs more than 44,000 people and works closely with the scientific and medical community to develop groundbreaking new therapies and improve diabetes treatment. Overall, Novo Nordisk has contributed significantly to improving the lives of millions of people with diabetes and other metabolic diseases. The company remains committed to further expanding its core business and continuously adapting to changing market conditions and customer needs.
Annual results
Reported figures, DKK · revenue up 6.4% in 2025
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | 309B | 102B | 33.1% | 29.0B |
| 2024 | 290B | 101B | 34.8% | 69.7B |
| 2023 | 232B | 83.7B | 36.0% | 70.0B |
| 2022 | 177B | 55.5B | 31.4% | 64.1B |
| 2021 | 141B | 47.8B | 33.9% | 47.6B |
Dividends per share
Recent SEC filings
NVO in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Novo Nordisk A/S are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Filings from SEC EDGAR. Reported figures, not investment advice.